At a glance
- Originator Teijin Pharma
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hypercholesterolaemia
Most Recent Events
- 29 Apr 1996 Discontinued-Preclinical for Atherosclerosis in Japan (Unknown route)
- 29 Apr 1996 Discontinued-Preclinical for Hypercholesterolaemia in Japan (Unknown route)
- 01 Feb 1995 Preclinical development for Atherosclerosis in Japan (Unknown route)